Skip to main content
. 2024 May 14;13(10):838. doi: 10.3390/cells13100838

Figure 6.

Figure 6

PKM2 inhibition sensitizes tumor cells to cisplatin. (A) ISLR level examined in tumor tissues from Balb/c mice; Balb/c mice were transplanted with 4T1 cells, and, 20 days later, 3 mg/kg cisplatin were intraperitoneal injected into the mice for 20 days. (B) Relative ROS levels measurement of 4T1 cells which were treated with 1 μM shikonin/1 μg/mL cisplatin or both reagents for 9 h. (C) Relative ROS levels measurement of 4T1 cells which were treated with 10 μM PKM2-IN-1/1 μg/mL cisplatin or both reagents for 9 h. (D,E) Relative live cell number of 4T1 cells which were treated with 1 μM shikonin/10 μM PKM2-IN-1, 1 μg/mL cisplatin, or both reagents for 9 h. (F) Experimental procedure presenting 4T1 cells transplantation into Balb/c mice and the dosing regimen. (G) Growth of tumors generated from 4T1 bearing Balb/c mice that were treated without (Vehicle) or with shikonin/cisplatin/both shikonin and cisplatin as indicated in (F). (H,I) Tumor weight (H) and tumor size (I) from tumor-bearing mice which were treated with different reagent. (J) Body weight of tumor bearing mice which were treated with different reagent. Data are means ± SEM (n = 3). Shi = Shikonin; Cis = Cisplatin; PI1 = PKM2-IN-1. * p < 0.05; ** p < 0.01; *** p < 0.001; ns, not significant.